Comprehensive Genomic Profiling PLUS

Caris Molecular Intelligence enables the delivery of precision medicine by providing oncologists with clinically actionable and individualized cancer treatment information to help personalize cancer care. Our Comprehensive Genomic Profiling PLUS (CGP+) approach to assess DNA, RNA and Proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions.

Clinical research studies continue to demonstrate the utility of Caris Molecular Intelligence and have demonstrated its positive effect on the overall survival (OS) outcomes of cancer patients. Two studies, one conducted on a large group of patients suffering from refractory, metastatic, or rare cancers in 2015 and the other on a cohort of ovarian cancer patients in 2014, showed that patients treated according to Caris Molecular Intelligence results experienced between 9-14 months longer survival and received one fewer cancer drugs (avoiding potential toxicities and extra cost of therapy), vs patients not treated according to Caris recommendations. Learn more.

Caris Molecular Intelligence provides therapeutic insights designed to aid oncologists in personalizing cancer therapies for their patients. Caris Molecular Intelligence allows physicians to:
• Navigate among therapies with potential benefit;
• Identify therapies that may not have been considered;
• Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs); and
• Match patients to clinical trials.

Based on the clinical literature, biomarker and therapeutic associations are best analyzed by specific technologies looking for explicit genomic and proteomic aberrations. As such, Caris examines DNA, RNA and proteins to decode a patient’s tumor and provide a more comprehensive tumor assessment. One technology may not be sufficient or clinically appropriate to provide an integrated picture of a tumor’s biology. Learn more about our profiling technologies.

The ordering physician will receive the results of the patient’s tumor analysis in a clinically actionable report. There are 3 ways to access patient reports:
• MI Portal: On-demand access to interactive reports, plus electronic ordering and many other extra features;
• Email: Fully interactive reports delivered in real-time, right to your inbox (MI Portal account required to enroll in email report deliver);
• Fax: Reports delivered in real-time — due to the limited nature of faxing, however, interactive report features and color options are unavailable.
View a sample report.

After the specimen and required paperwork have been received by Caris Life Sciences, the ordering physician will receive the report in approximately 8-14 days. International cases range from 10-21 days due to additional shipping/customs requirements.

Yes, every report includes the Clinical Trials Connector™ at no additional cost. The Clinical Trials Connector a clinical trials matching service that identifies open and enrolling clinical trials tailored to the lineage and/or biomarker profile of the patient’s tumor.

Caris Molecular Intelligence is performed in our state-of-the-art, 66,000 sq-ft laboratory in Phoenix, Arizona. Our laboratory holds the industry’s strictest quality and compliance accreditations, including ISO 15189, CAP, CLIA, NY State and CE Mark.

Yes, Caris Molecular Intelligence is typically reimbursed by Medicare and other insurance providers. Caris Life Sciences will bill the patient’s insurance company, and the patient is typically responsible for co-payments, co-insurance and/or the deductible, as required by law.

Depending on the profile ordered, the number of markers analyzed and technologies used, the cost will differ among the various tumor profiling options. Learn more.